↓ Skip to main content

Prolactinomas: evolution after menopause

Overview of attention for article published in Archives of Endocrinology and Metabolism, January 2016
Altmetric Badge

Mentioned by

facebook
1 Facebook page

Citations

dimensions_citation
17 Dimensions

Readers on

mendeley
31 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Prolactinomas: evolution after menopause
Published in
Archives of Endocrinology and Metabolism, January 2016
DOI 10.1590/2359-3997000000138
Pubmed ID
Authors

Maria Susana Mallea-Gil, Marcos Manavela, Analia Alfieri, Maria Carolina Ballarino, Alberto Chervin, Karina Danilowicz, Sabrina Diez, Patricia Fainstein Day, Natalia García-Basavilbaso, Mariela Glerean, Mirtha Guitelman, Débora Katz, Monica Graciela Loto, Marcela Martinez, Karina Miragaya, Daniel Moncet, Amelia Susana Rogozinski, Marisa Servidio, Graciela Stalldecker, Marcelo Vitale, Laura Boero

Abstract

Objetive The aim was to assess the evolution of tumor size and prolactin (PRL) levels in patients with micro and macroprolactinomas diagnosed and treated with dopamine agonists during fertile age, and the effects of suspension of drugs after menopause. Retrospective study, 29 patients with prolactinomas, 22 microadenomas and 7 macroadenomas, diagnosed during their fertile age were studied in their menopause; treatment was stopped in this period. Age at menopause was 49 ± 3.6 years. The average time of treatment was 135 ± 79 months. The time of follow-up after treatment suspension was 4 to 192 months. Results Pre-treatment PRL levels in micro and macroadenomas were 119 ± 57 ng/mL and 258 ± 225 ng/mL, respectively. During menopause after treatment suspension, and at the latest follow-up: in microadenomas PRL levels were 23 ± 13 ng/mL and 16 ± 5.7 ng/mL, respectively; in macroadenomas, PRL levels were 20 ± 6.6 ng/mL 5t5and 25 ± 18 ng/mL, respectively. In menopause after treatment suspension, the microadenomas had disappeared in 9/22 and had decreased in 13/22. In the group of patients whose tumor had decreased, in the latest follow-up, tumors disappeared in 7/13 and remained unchanged in 6/13. In macroadenomas, after treatment suspension 3/7 had disappeared, 3/7 decreased and 1/7 remained unchanged. In the latest control in the 3 patients whose tumor decreased, disappeared in 1/3, decreased in 1/3 and there was no change in the remaining. Conclusions Normal PRL levels and sustained reduction or disappearance of adenomas were achieved in most of patients, probably due to the decrease of estrogen levels. Dopamine agonists might be stopped after menopause in patients with prolactinomas.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 31 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 31 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 6 19%
Lecturer > Senior Lecturer 2 6%
Other 2 6%
Student > Doctoral Student 2 6%
Student > Master 2 6%
Other 7 23%
Unknown 10 32%
Readers by discipline Count As %
Medicine and Dentistry 14 45%
Veterinary Science and Veterinary Medicine 1 3%
Agricultural and Biological Sciences 1 3%
Nursing and Health Professions 1 3%
Psychology 1 3%
Other 1 3%
Unknown 12 39%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 May 2016.
All research outputs
#22,759,802
of 25,374,917 outputs
Outputs from Archives of Endocrinology and Metabolism
#648
of 800 outputs
Outputs of similar age
#341,828
of 399,679 outputs
Outputs of similar age from Archives of Endocrinology and Metabolism
#5
of 7 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 800 research outputs from this source. They receive a mean Attention Score of 3.3. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 399,679 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.